TB-500 is frequently discussed alongside BPC-157 in recovery and research circles. Unlike many peptides in this space, its parent molecule — Thymosin Beta-4 — actually has a documented history in registered pharmaceutical clinical trials, which makes it a useful case study in separating a naturally occurring protein's research record from the synthetic fragment sold under a research-chemical name.
What It Is
Thymosin Beta-4 (Tβ4) is a naturally occurring 43-amino-acid protein found throughout human tissue, playing a role in cell structure via actin regulation (actin is a protein involved in how cells move and change shape). "TB-500" typically refers to a shorter synthetic peptide fragment developed to mimic part of Tβ4's activity.
Proposed Mechanism
Tβ4's actin-binding role is central to its research interest: by regulating actin, it appears to influence cell migration, which is a core part of how the body forms new blood vessels (angiogenesis) and moves repair cells to injury sites. This is the mechanistic basis for its association with wound healing and tissue repair research.
What Research Has Explored
- Wound healing — one of the best-established research areas for Tβ4, across skin and other tissue types.
- Cardiac tissue repair — a well-documented area of pharmaceutical research following heart injury.
- Corneal and ophthalmic repair — studied in the context of dry eye disease and corneal healing.
- General tissue and muscle recovery — the area most often discussed in fitness and recovery communities.
Evidence Quality: A Real Clinical Trial History
This is what sets Thymosin Beta-4 apart from many other research peptides: a pharmaceutical formulation of the molecule was developed and studied in registered human clinical trials by a biopharmaceutical company (RegeneRx Biopharmaceuticals), including a Phase 2 trial studying its effects following heart attacks, along with separate clinical research programs in dermal wound healing and ophthalmic conditions like dry eye disease.
It's important to draw a clear distinction, though: those clinical trials involved a specific pharmaceutical-grade formulation developed and controlled by that company for defined medical indications. This is a different regulatory pathway and product than the "TB-500" research peptide sold in the broader research chemical market — even though both derive from the same underlying molecule. The existence of legitimate clinical trials for Tβ4 doesn't mean the same safety and efficacy data automatically applies to research-grade TB-500 products.
Safety & Research Considerations
Given the difference between clinically-developed formulations and research-market TB-500, treat TB-500 as an investigational compound with an encouraging — but not directly transferable — clinical backstory. Product purity and accurate labeling matter significantly here, since the compound's real-world research value depends on it actually matching its intended structure. See our supplier checklist for what to look for.
Bottom Line
TB-500/Thymosin Beta-4 has one of the more substantiated research backstories in this space, including genuine human clinical trial history for its parent molecule — but that history belongs to a specific pharmaceutical development program, not directly to research-grade TB-500 products.
ZenoPeps offers third-party tested TB-500 with a Certificate of Analysis included, for research use.
Visit the Store →